Comprehensive Characterisation and Therapeutic Evaluation of EGFR-Targeted Gelatin Nanoparticles for Cancer Therapy | Chapter 4| Medical Science: Recent Advances and Applications Vol. 11

 

The emergence of nanotechnology-based drug delivery systems has revolutionized cancer treatment by enabling targeted therapeutic approaches that can specifically accumulate within tumor tissues while minimizing off-target effects. Epidermal growth factor receptor (EGFR)-targeted gelatin nanoparticles represent a promising approach for cancer therapy through selective drug delivery to EGFR-overexpressing tumour cells. A better understanding of the biological barriers and the pathophysiological principles of GE11- modified tumor-targeting nanoparticles will be promoted, especially through the study of the targeting delivery process of GE11 peptide-modified liposomes. This research paper comprehensively examines the observation methods and analytical processes for characterizing EGFR-targeted gelatin nanoparticles, focusing on their synthesis, modification, and therapeutic applications. The study evaluates various characterisation techniques including transmission electron microscopy (TEM), scanning electron microscopy (SEM), dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), and in vitro cellular assays. The methodology encompasses both experimental design principles and analytical protocols based on established practices in the literature. Secondary data analysis was conducted through a comprehensive review of recent literature published between 2020-2024. A total of 40 peer-reviewed publications were systematically analyzed to extract quantitative data on nanoparticle properties, targeting efficiency, and therapeutic outcomes. Primary data analysis encompasses original research findings from laboratory studies conducted to evaluate EGFR-targeted gelatin nanoparticle systems. The analysis includes experimental data from nanoparticle synthesis, characterisation, and biological evaluation studies. Primary data analysis reveals that GE11 peptide-modified gelatin nanoparticles demonstrate enhanced cellular uptake in EGFR-positive cancer cell lines, with particle sizes ranging from 150-300 nm and encapsulation efficiencies exceeding 85%. Secondary data analysis from recent studies indicates significant therapeutic improvements, with targeted formulations showing 60-75% greater efficacy compared to non-targeted controls in various cancer models. The findings demonstrate that multi-modal characterization approaches are essential for optimizing EGFR-targeted gelatin nanoparticle systems, providing critical insights for translating these therapeutic platforms from laboratory research to clinical applications. The successful translation of these research findings into clinical applications has the potential to significantly improve outcomes for cancer patients while reducing treatment-related side effects.

 

 

Author(s) Details

Huda Begam
Department of Chemistry, RKDF University, Gandhi Nagar, Bhopal (M.P.) 462033, India.

Please see the book here :- https://doi.org/10.9734/bpi/msraa/v11/6292